Ahead of an impending split, Galenica gains U.S. and Japan marketing rights for Veltassa® (patiromer), with the acquisition of Relypsa in a deal worth US$1.53 B. Galenica’s Vifor Pharma unit already held the ex-U.S. and Japan marketing rights for Veltassa (Deal No. 65968), and thus now has full global rights to this drug. Veltassa was launched in the US in December 2015 for hyperkalaemia in patients with heart failure or chronic kidney disease and is currently under review by the EMA in Europe.